RESUMO
Objective To observe the curative effect of Bairui Granules combined with amoxicillin and clavulanate potassium tablets in treating acute tonsillitis. Methods A total of 200 patients with acute tonsillitis treated in Dongfang Hospital from February to November in 2017 were randomly divided into the treatment group and the control group according to the random number table method. A total of 100 cases in the control group was treated with amoxicillin and clavulanate potassium tablets, 100 cases in the treatment group received Bairui Granules combined with amoxicillin and clavulanate potassium tablets, each group was treated for 5 d as one course. The clinical symptoms and signs improving time of two groups were observed and the therapeutic effects of the two groups were compared and analyzed. Result In the treatment group, the time of heat withdrawal and sore throat disappeared was significantly less than that of the control group (P < 0.01); After one course of treatment, the total effective rate of the treatment group was significantly higher than that of the control group (P < 0.05). In the two groups, there was no adverse reaction during the treatment. Conclusion Bairui Granules combined with amoxicillin and clavulanate potassium tablets had the advantages of short course and higher effect in the treatment of acute tonsillitis.
RESUMO
OBJECTIVE: To establish an HPLC-UV-ESI-MSn method for the study of impurity profile of amoxicillin and clavulanate potassium tablets. METHODS: Agilent 1100 LC/MSD Trap liquid chromatography-mass spectrometry was used, and the column was Shim pack CLC-ODS RP18(4.6 mm×250 mm, 5 μm). The mobile phase A was 20 mmol·L-1 ammonium acetate (pH adjusted to 6.0), and the mobile phase B was 20 mmol·L-1 ammonium acetate-acetonitrile (20∶80) (pH adjusted to 6.0). Gradient elution was performed at a flow rate of 1.0 mL·min-1. ESI source was used. Positive and negative ion scan was conducted with a scanning range of m/z 100-1 500. The nebulizing pressure was 275.8 kPa, dry gas flow was 9 L·min-1, and post-column diversion ratio was 1∶5. Some related substances were identified by comparing the retention time in the chromatography, [M+H]+ spectrum and MS2 spectrum with those of the reference substances, while the others which do not have reference substances were deduced or speculated by analyzing the MS2 or MSn fragmentation with the help of a rule summarized from the MS2 fragmentation of amoxicillin, clavulanic acid and system suitability impurity reference substances. RESULTS: A total of 15 related substances were separated and characterized including nine known impurities like amoxicilloic acid, amoxicillin dimer, etc. and six unknown impurities. CONCLUSION: The method can be applied in the identification and qualitative analysis of the related substances in amoxicillin and clavulanate potassium tablets and is helpful for the quality control and optimization of the synthetic process.
RESUMO
Objective To evaluate the effect of treatment and compliance of rebeparzole sodium enteric coated capsules, amoxicillin and clavulanate potassium tablets and furazolidon or levofloxacine treatment of helicobacter pylori infection.Methods Two hundred and forty-nine cases of positive helicobacter pylori infection were randomly divided into three groups.Eighty-one cases of Group A were treated with rebeparzole sodium enteric-coted capsules (20 mg one time), amoxicillin and clavulanate potassium tablets (3 tablets one time) and furazolidon(100 mg one time) ,twice a day before breakfast and supper.Eighty-three cases of Group B were treated with rebeparzole sodium enteric-coted capsules (20 mg one time), amoxicillin and clavulanate potassium tablets (3 tablets one time) and levofloxacine (200 mg one time), twice a day before breakfast and supper.Eighty-five cases of Group C were treated with rebeparzole sodium enteric-coted capsules (20 mg one time) ,clarithromycin capsules(500 mg one time) and amoxicillin dispersible tablets(1 000 mg one time) ,twice a day before breakfast and supper.Period of treatment was 10 days.Results The helicobacter pylori eradication rate of Group A,B and C were 93.83％(76/81) ,89.16％(74/83) and 81.18％(69/85).The eradication rate of Group A was higher than that of Group C (P＜0.05).The comparison between Group A and Group B and between Group B and Group C had no statistically significant difference(P＞0.05).Total integral in average of main digestive symptoms respectively decreased from 12.52±2.24, 12.30±2.42,12.61±2.01 to 3.16±2.23, 3.58±2.39,4.78±2.28 after four-week treatment.The effect of treatment of Group A and Group B was much better than that of Group C(P＜0.05).The incidence of adverse reaction were 11.11％, 30.12％ and 62.35％respectively.Group A and Group B were much lower than Group C (P ＜ 0.05), and Group A was lower than Group B(P＜0.05).In the comparison of the spread of compliance, Group A was the best, the next was Group B,and the last was Group C.The comparison result of those 3 groups was statistically significant (P ＜0.05).Conclusion Ray rabeprazole sodium enteric coated capsules and amoxicillin and clavulanate potassium dispersion tablets combined with furazolidone furazolidone triple therapy in the treatment of Helicobacter pylori Helicobacter pylori infection effect is the best.